The iPortVR is a vitreoretinal oculosubarachnoid glaucoma device (VOGD), inserted via the ab-interno pathway. The device creates a micro shunt communication between the ocular posterior chamber and the retrolaminar subarachnoid space.
Through oculosubarachnoid shunting, the iPortVR aims to offer the same highly effective IOP control demonstrated by the OptiShunt. By making use of ab-interno implantation, the iPortVR is designed to be fast, simple and minimally invasive to insert.
The iPortVR is the first ever glaucoma device designed for use during vitreoretinal(VR) surgery. VR surgery is commonly associated with glaucoma. iValve technology built into the design makes the iPortVR compatible for use with all VR tamponading agents.
Pre-clinical testing of the iPortVR is currently underway. The Glaucoma treatment by Oculosubarachnoid Vitreoretinal Implant Device (GOVID) study is the iPortVR early feasibility study planned to kick off in 2021.